Development of Neuropathic Arthropathy With Entrectinib: Case Report
- PMID: 36340796
- PMCID: PMC9634017
- DOI: 10.1016/j.jtocrr.2022.100419
Development of Neuropathic Arthropathy With Entrectinib: Case Report
Abstract
TRK inhibition can lead to on-target neurologic adverse events. Two cases illustrate the development of neuropathic arthropathy as a side effect of entrectinib. After starting entrectinib, both patients developed foot pain, swelling, and sensory changes with magnetic resonance imaging revealing marrow edema. Providers should have a low threshold to investigate foot pain or gait abnormalities thoroughly with magnetic resonance imaging and referral to specialists to aid in the diagnosis of neuropathic arthropathy, with consideration to transition to an alternative agent.
Keywords: Case report; Entrectinib; NTRK; Neuropathic Charcot arthropathy.
© 2022 The Authors.
Figures


References
-
- Trieb K. The Charcot foot. Bone Joint J. 2016;98-B:1155–1159. - PubMed
-
- Delgado J., Pean E., Melchiorri D., et al. The European Medicines Agency Review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements. ESMO Open. 2021;6 - PMC - PubMed
-
- Lv F., Xu X-Jie, Song Y.W., et al. Recurrent and novel mutations in the NTRK1 gene lead to rare congenital insensitivity to pain with anhidrosis in two Chinese patients. Clin Chim Acta. 2017;468:39–45. - PubMed
Publication types
LinkOut - more resources
Full Text Sources